

EARLY START FOR BETTER¹

POSSIBILITIES

FOR PEOPLE WITH UNCONTROLLED TYPE 2 DIABETES

RYBELSUS[®]
semaglutide tablets 3mg | 7mg | 14mg

A GAME CHANGER. A LIFE CHANGER

This is a model and not a patient

Dear Doctor,
Early and aggressive control is associated with
legacy effect in **PwDs** to **prevent future
diabetes related complication**²



8 out of 10

PwDs achieved
glycaemic^{#3}
target of <7%



1 in 3

PwDs achieved a
weight loss^{#3}
of >5%



~45%

PwDs achieved
normoglycaemia
(<6%) in PwDs³



Visit HCP Portal to learn more

Abbreviations:

PwDs: People with Diabetes

References:

% when oral semaglutide is initiated within
1 year of T2D diagnosis

#achieved a glycemic target of <6%

1. ADA, Standards of Care in Diabetes-2024.
Diabetes Care 1 January 2024; 47

2. Folz, R., et al. Diabetologia 64, 2131–2137 (2021).

3. Goldenberg R et al. Can J Diabetes. 2021; 45(7):S28-29

**Abbreviated prescribing
information**

[Click here to read Rybelsus API](#)

Disclaimer:

Apis bull is a registered trademark of Novo Nordisk A/S.
Not real images of patients, only for illustrative purposes.

For the use only of registered medical practitioner
or a hospital or a laboratory